Vol.3 No.14 2005/07/28 2005/07/20 1. FDA MedWatch 2005/07/08 2005 Safety Alert:[ Cialis ] tadalafil [ Levitra ] vardenafil hydrochloride [ Viagra ] sildenafil citrate [ Cialis ] tadalafil [ Levitra ] vardenafil hydrochloride [ Viagra ] sildenafil citrate
PDE5 cGMP-specific type 5 phosphodiesterase
PDE5 cGMP-specific type 5 phosphodiesterase
PDE5 cGMP-specific type 5 phosphodiesterase
2. FDA Public Health Advisory 2005/07/13 Suspended Marketing of [ Palladone ] hydromorphone hydrochloride, extended release capsules [ Palladone ] hydromorphone hydrochloride 3. Alert for Healthcare Professionals 2005/07/15 Fentanyl Transdermal System marketed as [ Duragesic ] Fentanyl [ Duragesic ] FDA ALERT [07/2005]: Narcotic Overdose and Death 3-1 FDA MedWatch 2005/07/08 2005 Safety Alert: [ Duragesic ] fentanyl transdermal system [ Duragesic ] fentanyl transdermal system 3-2 FDA Public Health Advisory 2005/07/15 Safety Warnings Regarding Use of Fentanyl Transdermal Skin Patches Fentanyl 4. CDER 2005/07/18 Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies as of July 18, 5.FDA MedWatch 2005/07/18 2005 Safety Alert: [ Natrecor ] nesiritide [ Natrecor ] nesiritide 6. FDA Public Health Advisory 2005/07/19 Sepsis and Medical Abortion [ Mifeprex ] mifepristone [ Mifeprex ] mifepristone 7. FDA MedWatch 2005/07/01 Important Drug Warning Regarding [ Raptiva ] efalizumab [ Raptiva ] efalizumab Health Canada 1. Public Advisory 2005/07/04 New Safety Information on the Use of [ Depo-Provera ] medroxyprogesterone acetate suspension for injection, 150 mg IM associated with Bone Mineral Density Changes [ Depo-Provera ] medroxyprogesterone acetate Important Safety Update: Potential effect of [ Depo-Provera ] medroxyprogesterone acetate injectable suspension, USP on Bone Mineral Density BMD changes in adults and adolescents 2005/07/07 [ Depo-Provera ] medroxyprogesterone 2. Public Advisory 2005/07/07 Reminder: Canadian Requirements for White Blood Cell Monitoring for Patients Taking [ Clozaril ] clozapine Tablets. [ Clozaril ] clozapine
MARTA multi acting receptor targeted agents
3. Advisory 2005/07/12 Health Canada advises consumers about important safety information on statins Health Canada 4. Warning 2005/07/14 Health Canada warns consumers not to use certain Ayurvedic medicinal products Health Canada
Journal of the American Medical Association JAMA
5. New safety information regarding the co-administration of [‘Videx’] and [‘Viread’], and either [‘Sustiva’] or [‘Viramune’] 2005/07/18 [ Videx ] didanosine ddI [ Viread ] tenofovir disoproxil fumarate TDF [ Sustiva ] efavirenz EFV [ Viramune ] nevirapine NVP
[ Viread ] tenofovir disoproxil fumarate TDF
NZ MEDSAFE 1. Prescriber Update Vol.26 No.1 2005/06 Prescribing restrictions for all COX-2 inhibitors 2005/04/29
Medicines Adverse Reactions Committee MARC
Comunicat de Londres Cap a l'Espai europeu d'educació superior: responent als reptes d'un món globalitzat I. Prefaci 1.1 Els ministres responsables de l'educació superior dels països que participen en el Procés de Bolonya, ens hem reunit a Londres per verificar els progressos des de la reunió celebrada a 1.2 D'acord amb els criteris acordats perquè un país s'incorpori
5.6. Fragen zu Niere und Wasserhaushalt Wasserhaushalt (3) Die Teilchenkonzentration (Osmolarität) des Extrazellulärraums kann durch äußere Faktoren beeinflusst werden. Wie ändert sich in den folgenden Fällen die Osmolarität des EZR? Geben Sie jeweils eine Begründung. a) häufiges Erbrechen b) starkes Schwitzen c) achtstündige Skitour bei kalter, trockener Luft. Lösung a